Please provide your email address to receive an email when new articles are posted on . Long-acting injectable paliperidone use was associated with significant improvement in clinical and functional ...

Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone ...

TITUSVILLE, N.J., Nov. 19, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

April 12, 2011 — The US Food and Drug Administration (FDA) has approved paliperidone (Invega; Ortho-McNeil-Janssen Pharmaceuticals) for the treatment of schizophrenia in adolescent patients aged 12 to ...

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...

(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...

Janssen, L.P.'s INVEGA Approved By FDA As New Treatment For Schizophrenia TITUSVILLE, N.J., Dec. 20 /PRNewswire/ -- First Oral Extended Release Medication to Treat Schizophrenia. The U.S. Food and ...

Independent Data Monitoring Committee Recommends Halting Trial and Unblinding Data Based on Treatment Efficacy TITUSVILLE, N.J., March 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ...